- About Us
- Educational Activities
- Receive CME Credits
- Course Documents
- Travel & Accommodations
- Contact Us
Thursday, March 19 - Saturday, March 21, 2015
New York, NY
Check back for course updates!
The NYU Seminar in Advanced Rheumatology is an informative conference for rheumatologists, orthopedists, trainees in the rheumatic diseases and internists and other physicians with a special interest in rheumatology. It will review and address those areas where recent, solid knowledge in the treatment of rheumatic diseases is available, focusing particularly on the state-of-the-art in rheumatology, at the leading edge between new clinical knowledge and its translation into practice.
Rheumatology is a fast-moving field in which new discoveries are continually being made, and new treatment modalities developed. Because the basic and clinical scientific underpinnings of rheumatologic practice frequently and directly come to impact upon therapy, this course will also explore those areas of new science that are likely to prove important to the near-future management of patients with rheumatic disease.
Lectures and Year-In-Review updates will provide participants with the latest information in arthritis, lupus and other rheumatologic conditions; panel discussions and optional Meet-the-Professor sessions will allow participants to raise questions and participate in dialog with the course instructors and clinical experts.
Our target audience consists of clinical and academic rheumatologists, orthopedists, trainees in the rheumatic diseases and internists with a special interest in rheumatology; other interested clinicians are welcome.
Statement of Need
Lupus management remains a core performance area in which rheumatologists require updating. A number of recent research results have clinical implications that are being gradually translated into care. Clinicians need to be aware of newer approaches to the treatment of lupus, including the central role of hydroxychloroquine, the expanding use of mycophenolate mofetil, the recent introduction of belimumab and the potential for new agents in the near future. Physicians must also be prepared to incorporate new thinking in regards to pathophysiology, genetics and the role of cytokines, as well as to be aware of the co-morbid conditions of SLE, including cardiac and neurologic disease, and their best management. Management of pregnancy in lupus patients presents unique challenges. Physicians caring for such patients must be able to recognize the potential for adverse outcomes in both the mother and the fetus (neonatal lupus), and the best ways of managing concurrent lupus and pregnancy.
There are new approaches to the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis, including newly-available biologic therapies and small-molecule signal transduction inhibitors, as well as the potential for directly managing bone erosion. Clinicians need to be able to incorporate these new approaches into treatment paradigms, considering both safety and efficacy. With the aging of the population osteoporosis has become an increasingly prevalent disease, and the screening and management of osteoporosis are evolving as a result of new insights into disease risk, bone biology and pharmacologic development. Physicians need to stay abreast of the current recommendations for osteoporosis screening and management, including management of steroid-induced osteoporosis as well as osteoporosis in patients who fail or are unable to take standard therapies.
At the conclusion of this activity, participants should be able to:
• Evaluate new and future treatment approaches for lupus management
• Consider the roles of specific immune cells, genetics and cytokines in the pathogenesis of lupus, and the potential to exploit these factors as therapeutic targets
• Describe the potential risks to the pregnant lupus patient, including issues of lupus flare vs pre-eclampsia
• Describe the potential risks to the fetus of autoimmune mothers, particularly neonatal lupus. Clinicians should be able to apply the most recent recommendations for screening, following and managing pregnant lupus patients and their fetuses and offspring
• Recognize the benefits, and manage risks of newly available biologic therapies for treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis
• Develop strategies to determine when to introduce small-molecule biological therapies into treatment
• More effectively screen patients for osteoporosis, including avoiding unnecessary testing
• Appropriately select anti-osteoporosis drugs, including managing potential toxicities of treatment, and should be able to apply second-line approaches when first-line agents are ineffective or contraindicated